课题基金 / 基金详情

Brain-Gut Microbiome-Immune Axis in Hypertension

Brain-Gut Microbiome-Immune Axis in Hypertension
高血压中的脑肠微生物组免疫轴
批准号:
9122989
负责人:
Carl J Pepine
金额:
$61.79万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-04-01 至 2020-03-31

项目摘要

项目成果

Carl J Pepine的其他基金

相似基金

相关文献

中文摘要
翻译
 描述(申请人提供):高血压(HTN)是心血管疾病(CVD)和直接影响CVD的疾病(如糖尿病、慢性肾脏疾病、阻塞性睡眠呼吸暂停等)最常见的可改变风险。尽管生活方式的改变和药物治疗的进步,大约20%的HTN患者对抗高血压药物耐受(或需要≥3)。耐药HTN(R-HTN)通常起源于神经源性,并与自主神经系统功能障碍相关。在最近经皮肾动脉交感神经切断失败后,几乎没有可用的治疗选择(SYMPLICITY HTN-3,Prauge-15)。因此,以机制为基础的突破势在必行,以开发新的策略来控制和潜在地治愈R-HTN。我们认为,R-HTN的肠道生物失调和脑-肠道-骨髓(BM)功能失调的证据代表了这一突破。我们提出了脑-肠道-骨髓功能失调相互作用假说:HTN危险因素通过影响自主脑区域,启动一系列关键信号事件,从而增加交感神经动力,这是建立神经源性R-HTN的关键。这包括增加肠道僵硬、通透性和炎症,导致肠道微生物失调。与生物失调相关的变化增加了髓系祖细胞和其他前炎症细胞的骨髓生成。这导致外周炎症和神经炎症增加,因为一些骨髓来源的髓系祖细胞迁移到室旁核(PVN),并分化为小胶质细胞。因此,我们假设R-HTN的建立是由SNA介导的肠道生物失调、骨髓促炎细胞活性和神经炎症引起的。为了支持/反驳R-HTN中脑-肠道-骨髓相关的神经炎症假说,我们提出了三个具体的目标:目的1将探讨肠道SNA增加在HTN的肠道通透性增强、促炎状态和微生物失调中起关键作用的假说。目标2将定义肠道生物失调如何增加HTN中前炎症前体细胞的产生和神经炎症。目的3将评估这样一种假设,即人类R-HTN与严重的肠道微生物失调有关,米诺环素治疗将逆转这种失调并降低血压。这些研究将利用最先进的综合生理基因组技术,并将由一支特殊的研究团队进行。因此,这项从小鼠到人类的基于机制的翻译研究的结果将为开发改变范式的R-HTN治疗方法提供基础,而不涉及更多的抗高血压药物。
英文摘要
 DESCRIPTION (provided by applicant): Hypertension (HTN) is the most prevalent modifiable risk for cardiovascular disease (CVD) and disorders directly influencing CVD (i.e. diabetes, chronic kidney disease, obstructive sleep apnea, etc.). Despite lifestyle changes and advances in drug therapy, ~20% of all HTN patients are resistant to (or require ≥3) antihypertensive drugs Resistant HTN (R-HTN) is generally neurogenic in origin and associated with a dysfunctional autonomic nervous system. Few treatment options remain available following the recent failure of percutaneous renal artery sympathetic denervation (SYMPLICITY HTN-3, PRAUGE-15). Thus, a mechanism- based breakthrough is imperative to develop novel strategies to control and potentially cure R-HTN. We believe that our evidence of gut dysbiosis and dysfunctional brain-gut-bone marrow (BM) interaction in R-HTN represents this breakthrough. We propose a brain-gut-BM dysfunctional interaction hypothesis: HTN risk factors increase sympathetic drive by influencing autonomic brain regions, setting in motion a sequence of critical signaling events key to establishing neurogenic R-HTN. This includes increased gut stiffness, permeability and inflammation leading to gut microbial dysbiosis. Dysbiosis-associated changes increase BM production of myeloid progenitors and other proinflammatory cells. This contributes to increased peripheral inflammation, and neuroinflammation, as some BM-derived myeloid progenitors migrate to the paraventricular nucleus (PVN), and differentiate into microglia. Therefore, we hypothesize that establishment of R-HTN is caused by an increased SNA-mediated gut dysbiosis, activity of BM proinflammatory cells, and neuroinflammation. Three specific aims are proposed to support/refute this dysfunctional brain-gut-BM linked neuroinflammation hypothesis in R-HTN: Aim 1 will investigate the hypothesis that increased gut SNA is critical in enhanced intestinal permeability, proinflammatory conditions, and microbial dysbiosis in HTN. Aim 2 will define how gut dysbiosis increases production of proinflammatory progenitors and neuroinflammation in HTN. Aim 3 will evaluate the hypothesis that human R-HTN is linked to profound gut microbial dysbiosis and that treatment with minocycline will reverse the dysbiosis and lower BP. These studies will utilize state-of-the-art integrative physiological genomic techniques and will be conducted by an exceptional team of investigators. Thus, the outcome of this mechanism-based translational study spanning from mice to humans will provide the basis for development of paradigm-changing therapeutic approaches for R-HTN without involving more anti-hypertensive drugs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Ancillary Functional Studies for the CCTRN
  • 批准号:
    7689238
  • 项目类别:
  • 资助金额:
    $36.72万
  • 财政年份:
    2008
  • 负责人:
    Carl J Pepine
  • 依托单位:
Ancillary Functional Studies for the CCTRN
  • 批准号:
    7900922
  • 项目类别:
  • 资助金额:
    $36.72万
  • 财政年份:
    2008
  • 负责人:
    Carl J Pepine
  • 依托单位:
Ancillary Functional Studies for the CCTRN
  • 批准号:
    8112726
  • 项目类别:
  • 资助金额:
    $36.72万
  • 财政年份:
    2008
  • 负责人:
    Carl J Pepine
  • 依托单位:
UFCC for Cardiovascular Cell Therapy Research Network
  • 批准号:
    7337115
  • 项目类别:
  • 资助金额:
    $53.72万
  • 财政年份:
    2007
  • 负责人:
    Carl J Pepine
  • 依托单位:
海外基金